Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Hormonal manipulation of benign prostatic hyperplasia.

Rick FG, Saadat SH, Szalontay L, Block NL, Kazzazi A, Djavan B, Schally AV.

Curr Opin Urol. 2013 Jan;23(1):17-24. doi: 10.1097/MOU.0b013e32835abd18. Review.

PMID:
23202285
2.

Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.

Rick FG, Schally AV, Block NL, Abi-Chaker A, Krishan A, Szalontay L.

Prostate. 2013 Jun;73(8):873-83. doi: 10.1002/pros.22633. Epub 2012 Dec 31.

PMID:
23280565
3.

Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).

Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS.

BJU Int. 2011 Aug;108(3):388-94. doi: 10.1111/j.1464-410X.2011.10195.x. Epub 2011 Jun 1.

4.
6.

Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.

Ross AE, Feng Z, Pierorazio PM, Landis P, Walsh PC, Carter HB, Trock BJ, Schaeffer EM.

BJU Int. 2012 Sep;110(5):651-7. doi: 10.1111/j.1464-410X.2011.10875.x. Epub 2012 Jan 30.

7.
8.

Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.

Rick FG, Szalontay L, Schally AV, Block NL, Nadji M, Szepeshazi K, Vidaurre I, Zarandi M, Kovacs M, Rekasi Z.

J Urol. 2012 Apr;187(4):1498-504. doi: 10.1016/j.juro.2011.11.081. Epub 2012 Feb 17.

PMID:
22341819
9.

[Cost-effectiveness of the combination therapy of dutasteride and tamsulosin in the treatment of benign prostatic hyperlasia in Spain].

Antoñanzas F, Brenes F, Molero JM, Fernández-Pro A, Huerta A, Palencia R, Cozar JM.

Actas Urol Esp. 2011 Feb;35(2):65-71. doi: 10.1016/j.acuro.2010.11.008. Epub 2011 Jan 26. Spanish.

PMID:
21269736
10.

A review of combination therapy in patients with benign prostatic hyperplasia.

McVary KT.

Clin Ther. 2007 Mar;29(3):387-98. Review.

PMID:
17577460
11.

[Comment to: «Cost-Effectiveness of the combination therapy of dutasteride and tamsulosin in the treatment of benign prostatic hyperlasia in Spain»].

Miñana B.

Actas Urol Esp. 2011 Feb;35(2):72. doi: 10.1016/j.acuro.2010.12.002. Epub 2011 Feb 15. Spanish. No abstract available.

PMID:
21324551
12.

Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.

DerSarkissian M, Xiao Y, Duh MS, Lefebvre P, Swensen AR, Bell CF.

J Manag Care Spec Pharm. 2016 Oct;22(10):1204-14. doi: 10.18553/jmcp.2016.22.10.1204.

13.

Dutasteride for the treatment of prostate-related conditions.

Slater S, Dumas C, Bubley G.

Expert Opin Drug Saf. 2012 Mar;11(2):325-30. doi: 10.1517/14740338.2012.658040. Epub 2012 Feb 8. Review.

PMID:
22316171
14.
15.

The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.

Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, Mirone V, Castro R, Wilson T, Montorsi F; CombAT Study Group.

Eur Urol. 2009 Feb;55(2):461-71. doi: 10.1016/j.eururo.2008.10.037. Epub 2008 Nov 6.

PMID:
19013011
16.

Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.

Logan YT, Belgeri MT.

Am J Geriatr Pharmacother. 2005 Jun;3(2):103-14. Review.

PMID:
16129387
17.
18.

Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.

Montorsi F, Henkel T, Geboers A, Mirone V, Arrosagaray P, Morrill B, Black L.

Int J Clin Pract. 2010 Jul;64(8):1042-51. doi: 10.1111/j.1742-1241.2010.02428.x. Epub 2010 May 7.

PMID:
20487046
19.

Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.

Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, Rittmaster RS.

Urology. 2011 Sep;78(3):641-6. doi: 10.1016/j.urology.2011.03.063. Epub 2011 Jul 20.

PMID:
21764428
20.

Finasteride versus dutasteride: a real-world economic evaluation.

Fenter TC, Runken MC, Black L, Eaddy M.

Am J Manag Care. 2007 Feb;13 Suppl 1:S23-8.

Supplemental Content

Support Center